Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of “Hold” by Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been given a consensus recommendation of “Hold” by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.06.

Several analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th.

Insider Transactions at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $3.25, for a total transaction of $97,500.00. Following the completion of the transaction, the director directly owned 6,188,287 shares in the company, valued at approximately $20,111,932.75. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 131,937 shares of company stock valued at $478,874 in the last ninety days. Corporate insiders own 6.65% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after buying an additional 7,407,606 shares in the last quarter. ARK Investment Management LLC increased its stake in shares of Recursion Pharmaceuticals by 11.2% in the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares in the last quarter. State Street Corp raised its holdings in Recursion Pharmaceuticals by 38.7% in the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after purchasing an additional 7,064,963 shares during the period. Geode Capital Management LLC raised its holdings in Recursion Pharmaceuticals by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock worth $44,731,000 after purchasing an additional 1,310,695 shares during the period. Finally, Norges Bank purchased a new position in Recursion Pharmaceuticals during the fourth quarter worth approximately $23,473,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $3.34 on Monday. The company has a market capitalization of $1.79 billion, a PE ratio of -3.21 and a beta of 1.03. The company’s fifty day moving average price is $3.32 and its 200-day moving average price is $3.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. Recursion Pharmaceuticals has a one year low of $2.77 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same quarter in the prior year, the firm posted ($0.41) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals will post -0.92 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.